Professor Shoumitro (Shoumi) Deb
Imperial College London
Professor Shoumitro (Shoumi) Deb is a Visiting Professor of Neuropsychiatry at the Imperial College London, UK. Previously he was a full-time substantive Clinical Professor at the University of Birmingham and a Senior Lecturer in Psychiatry at Cardiff University. His seminal works include the first-ever comprehensive neuropsychiatric outcome study in adults with traumatic brain injury (TBI), development of patient and carer determined outcome measures for patients with TBI, the first-ever comprehensive assessment of psychopathology in adults with intellectual disabilities and epilepsy, a dementia screening instrument for adults with intellectual disabilities which has been translated into more than 24 languages and validated independently, first-ever freely available accessible (easy read) psychotropic medication information leaflets online, and the first-ever online training for support staff to help reduce the overmedication of people with intellectual disabilities. He has also conducted the only published RCT (feasibility) on risperidone versus placebo to treat aggression in adults with TBI. He has about 300 publications and made over 250 presentations at national and international conferences (including many Keynote speeches). His citation index is 7350, h-Index, 46, and i-10, 96 (Google Scholar, 18.03.22). He has received research grants from the UK National Institute for Health Research (NIHR), the UK Wellcome Trust, and other charities and led a team of 21 research and teaching staff. He was the Programme Director for the MSc in Epilepsy course and module leader for the MSc in Neuropsychiatry at the University of Birmingham, and the Programme Director for the MSc in Psychological Medicine at Cardiff University, UK. He was a member of the first UK NICE Guideline Development Group in epilepsy and was also a Fellow of the UK NIHR. He was a member of the WHO Working Group on ICD-11 and led the development of the first-ever European Guideline (and recent update in 2022) on psychiatric diagnosis in adults with intellectual disabilities, and national and international guidelines on the use of psychotropic medication in this population.